Lupin Limited has announced the launch of Topiramate Extended-Release Capsules in the United States. The company got approval for this product from the US Food and Drug Administration (USFDA).
The new capsules come in strengths of 25 mg, 50 mg, 100 mg, and 200 mg. Lupin says these capsules work the same as the brand-name drug Trokendi XR®, which is sold by Supernus Pharmaceuticals.
This medicine is used to treat partial-onset seizures and primary generalized tonic-clonic seizures in patients six years and older. It can also be used with other medicines to treat these types of seizures and Lennox-Gastaut syndrome. Additionally, it helps prevent migraines in patients aged 12 and older.
According to coherent market insights, the Pharmaceutical Market is expected to grow at a CAGR of 8.1% during 2025 to 2032. Currently, the market is at USD 1.81 Tn in 2025 and is expected to be around USD 3.12 Tn by 2032. This significant growth trajectory is driven by the rising healthcare demands, advancements in drug development, and increasing investments in biopharmaceutical research worldwide, positioning the market for robust expansion over the forecast period.
Lupin pointed out that Topiramate Extended-Release Capsules have strong commercial potential, mentioning that these capsules are expected to make USD 164 million in annual sales in the US by December 2025, according to IQVIA MAT data.
Lupin Limited, which is based in Mumbai, is a global pharmaceutical company. It sells products in over 100 markets around the world. The company has 15 manufacturing plants and seven research centers in different countries, and employs over 24,000 people. Lupin is involved in many areas of medicine, such as central nervous system, respiratory, cardiovascular, anti-diabetic, gastrointestinal, anti-infective, and women’s health.
Source:
Newsroom: Tanmiah Food Company
Company: Tanmiah Food Company
